United Therapeutics

United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. The company was founded by Martine A. Rothblatt on June 26, 1996, and is headquartered in Silver Spring, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

United Therapeutics achieves record 2022 performance, eyes revenue doubling

United Therapeutics had a remarkable year in 2022, with strong financial performance and market acceptance of its products. While facing challenges and questions from analysts, UTHR remains focused on growth and innovation.

United Therapeutics reports robust Q1 growth and eyes new opportunities

United Therapeutics (UTHR) showcased strong revenue growth, product performance, and strategic investments in manufacturing facilities and pipeline trials. Challenges include managing factors affecting Tyvaso revenue and patient flow between key products. However, opportunities from new FDA approvals and organ manufacturing advancements position UTHR for continued growth and innovation.

United Therapeutics achieves record revenue, eyes growth beyond hypertension

United Therapeutics delivered exceptional financial performance in Q2 2023, driven by strong revenue growth and strategic product positioning.
The company's focus on combination therapies, expansion into new markets, and commitment to innovation position it well for future success.
Challenges in market saturation and limited drug options in certain therapeutic areas require targeted strategies and continued R&D efforts for sustained growth.
Overall, United Therapeutics' Q2 performance reflects a balance of strengths, challenges, and opportunities that shape its trajectory in the healthcare sector.

United Therapeutics reports record Q3 revenue and growth opportunities

United Therapeutics had a robust Q3 performance with record revenue and growth, driven by strong performance in the Tyvaso franchise. The company is strategically positioned for growth across its commercial business, pipeline programs, and organ technologies. While facing competition and trial challenges, UTHR remains optimistic about its growth potential and opportunities in addressing critical medical needs.

United Therapeutics reports record revenue growth and highlights innovative pipeline

United Therapeutics (UTHR) delivered a strong performance in Q4 2023, showcasing record revenue growth and confidence in its product portfolio. While facing challenges like patient demand fluctuations and potential competition, UTHR remains focused on innovation and growth opportunities in its pipeline.

United Therapeutics reports record revenue and advances in organ manufacturing

United Therapeutics (UTHR) delivered strong financial performance in Q1 2024, driven by revenue growth and strategic capital allocation initiatives.
The company's focus on product innovation, clinical advancements, and organ manufacturing positions UTHR well for future growth and market competitiveness.
While facing challenges in market penetration and product integration, UTHR has opportunities to expand its market presence, enhance treatment options, and pioneer advancements in organ transplantation.

United Therapeutics (UTHR) reports record revenue and strategic growth

United Therapeutics (UTHR) delivered a strong performance in Q2 2024, driven by record revenue and strategic product focus. The company's emphasis on innovation, market competitiveness, and employee satisfaction positions it well for future growth. Challenges in navigating market dynamics and executing key studies require focused attention, while opportunities exist in expanding market share and optimizing capital allocation.

United Therapeutics reports record revenue growth, faces litigation challenges

United Therapeutics delivered a strong performance in Q3 2024, achieving record revenue and significant growth in key product segments.
While facing challenges such as litigation accrual and slower growth in certain product revenues, the company remains well-positioned for future opportunities.
Investors have shown confidence in United Therapeutics, as reflected in the stock appreciation post ASR program, indicating positive market sentiment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2021 financial results before the market opens on Thursday, February 24, 2022. United Therapeutics will host a public webcast Thursday, February 24, 2022, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2021 Financial Results Before the Market Opens on Thursday, February 24, 2022

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (UT) (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, announced today that the world's first recipient of an investigational genetically-modified xenotransplanted organ, UT's UHeart™, reached a two-week milestone. University of Maryland School of Medicine (UMSOM) surgeons report continued post-operative cardiovascular improvement in the patien

United Therapeutics Corporation Announces Historic Achievements in its Xenotransplantation Programs

Amgen

Bristol-Myers

Gilead Sciences

Eli Lilly

Novocure

SPDR S&P Pharmaceuticals ETF

These seven pharmaceutical stocks could create lucrative opportunities in the new year The post 7 Pharmaceutical Stocks That Could Make You Rich appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.

7 Pharmaceutical Stocks That Could Make You Rich

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics' senior leaders will participate in a conversation hosted by J.P. Morgan biotech analyst Jessica Fye on January 6, 2022.

United Therapeutics Corporation to Webcast Executive Fireside Chat Conversation With J.P. Morgan Analyst

Columbus McKinnon

Comcast

Electronic Arts

Encompass Health

East West Bancorp

FedEx

General Motors

Graphic Packaging Hld

Global Payments

Huntsman

Lowe's

MKS Instruments

MasTec

Investors looking for stability in the new year may want to consider value stocks. Here are 15 of the best-rated ones heading into 2022.

The 15 Best Value Stocks to Buy for 2022

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

United Therapeutics (UTHR) Down 6% Since Last Earnings Report: Can It Rebound?

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics was named by Newsweek as one of America's Most Responsible Companies.

United Therapeutics Named by Newsweek as One of America's Most Responsible Companies 2022

United Therapeutics (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

United Therapeutics (UTHR) Q3 Earnings & Sales Beat, Stock Up

United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q3 2021 Results - Earnings Call Transcript

United Therapeutics (UTHR) delivered earnings and revenue surprises of 1.48% and 6.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Q3 Earnings and Revenues Surpass Estimates

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

United Therapeutics Corporation Reports Third Quarter 2021 Financial Results

United Therapeutics Corporation To Present At The Credit Suisse 30th Annual Healthcare Conference

United Therapeutics Corporation To Report Third Quarter 2021 Financial Results Before The Market Opens On Wednesday, November 3, 2021

United Therapeutics Details New Data Presented at CHEST Annual Meeting 2021

United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)

United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA

The stock price of United Therapeutics Corporation (NASDAQ: UTHR) fell by over 1% today. This is why it happened.

UTHR Stock: Why The Price Fell Today

MannKind

The FDA has issued a complete response to United Therapeutics Corporation (NASDAQ: UTHR) regarding the marketing application for Tyvaso DPI for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA's letter noted only a single deficiency related to an open inspection issue at a third-party facility that performs analytical testing of the treprostinil drug substance.

FDA Declines MannKind - United Therapeutics' Formulated Treprostinil For Lung Disease

United Therapeutics Provides an Update on the Progress of the Tyvaso DPI™ New Drug Application

United Therapeutics to Present New Data at CHEST Annual Meeting 2021

Clearside Biomedical

Innoviva

Mannatech

Oramed Pharmaceuticals

Veru

It's a great time to look beyond the big name pharmaceutical stocks and look for great niche players with big futures. The post 7 Top-Rated Pharmaceutical Stocks To Invest in for October appeared first on InvestorPlace.

7 Top-Rated Pharmaceutical Stocks To Invest in for October

United Therapeutics Converts to a Public Benefit Corporation Following Shareholder Approval

United Therapeutics Releases its Annual Corporate Responsibility Report

United Therapeutics Corporation (NASDAQ: UTHR) has presented new clinical data from the BREEZE study evaluating Tyvaso DPI (treprostinil) in patients with pulmonary arterial hypertension (PAH). Related Content: In June FDA Accepted Tyvaso DPI Application Under Priority Review.

United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients

United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data At The European Respiratory Society International Congress 2021

News for United Therapeutics Stock (UTHR)